Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cognitive impairment is a known consequence of cerebral small-vessel disease. Moderate to severe cognitive impairment has been shown in up to 60% of certain individuals with COPD and is likely to profoundly influence an individual's ability to manage their disease.

In addition to cerebral small vessel damage and cognitive dysfunction, other organs such as the heart, kidneys, and retina are likely to be susceptible to small-vessel damage in COPD. Several large population studies have shown that COPD is a significant independent risk factor for myocardial infarction, with the effect most marked in early, mild disease.

We propose to compare non-invasive MR brain imaging of white matter microstructure (diffusion tensor), cerebral perfusion (arterial spin labelling) and accumulated cerebral small vessel disease (cerebral microbleeds), in COPD patients to smokers without COPD. In addition we plan to explore mechanisms of cerebral small vessel disease in COPD by looking for associations between arterial stiffness, end organ vascular damage and cognitive function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COPD-Related Physiology and the Brain

NCT03269721

Pulmonary Disease, Chronic Obstructive (COPD) Cognitive Impairment

COMPLETED

Cerebral and Cardiac Blood Flow During Exercise in Patients With COPD

NCT04138563

COPD Cognitive Impairment

UNKNOWN

Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease

NCT06072690

Chronic Obstructive Pulmonary Disease Moderate Chronic Obstructive Pulmonary Disease Severe Cardiovascular Diseases +1 more

RECRUITING

Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease

NCT03184727

COPD Pulmonary Vascular Disorder Right Ventricular Dysfunction

UNKNOWN

Cognitive Impairment in COPD Patients

NCT04394299

COPD

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD

Stable, Non hypoxaemic, without history of vascular disease

No interventions assigned to this group

Healthy smokers

Age matched, smokers without COPD

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must give their signed and dated written informed consent
2. Subjects must be aged \>40 and ≤ 85
3. Subjects with a smoking history \> 10 pack years.
4. COPD group: Subjects with a FEV/FVC \<70%

Exclusion Criteria

1. Resting oxygen saturations \<92% on room air.
2. Long term oxygen therapy
3. Recent exacerbation of COPD (4 weeks)
4. Ischaemic heart disease
5. Cerebrovascular disease
6. Uncontrolled hypertension
7. Diabetes mellitus
8. Hepatic failure
9. Neurological disease
10. Non-cured tumours
11. Obstructive sleep apnoea
12. Current of past alcohol/drug abuse
13. Known history of dementia
14. Visual or hearing impairment that precludes neuropsychological assessment
15. Neuropsychological tests undertaken outside the study
16. Pregnant women or women who are lactating
17. Known alpha 1 anti-trypsin deficiency as a cause of their COPD
18. History of psychiatric disorders, or other conditions that will impact on the validity of their consent or interfere with compliance to perform study procedures.
19. Contra indication to MRI scanning -

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes